Description

BSE received clarifications from Nexus Surgical, Sheshadri Industries, and Takyon Networks regarding significant price/volume movements. Replies are still awaited from four other companies including Adhata Global and ZR2 Bioenergy.

Summary

BSE’s Surveillance Department (DOSS) issued Notice No. 20260513-12 on 13 May 2026, disclosing the status of clarifications sought from companies that experienced significant price and/or volume movements. Three companies have submitted replies, while four others have yet to respond.

Key Points

  • BSE observed significant price/volume movement in seven listed scrips and wrote to the respective companies for clarification
  • Replies have been received from three companies: Nexus Surgical and Medicare Ltd, Sheshadri Industries Ltd, and Takyon Networks Ltd
  • Four companies have not yet submitted replies: Adhata Global Ltd, Anuroop Packaging Ltd, Milgrey Finance & Investments Ltd, and ZR2 Bioenergy Ltd
  • The replies received are attached to the notice for reference by trading members and investors
  • Notice issued by the Surveillance Department under Deputy Vice President Sanjay Jain and Manager Shreya Ghose

Regulatory Changes

No new regulatory changes introduced. This is a disclosure notice under BSE’s ongoing surveillance framework to ensure trading members and investors have access to the latest relevant company information.

Compliance Requirements

  • Companies that have replied (Nexus Surgical & Medicare Ltd – 538874, Sheshadri Industries Ltd – 539111, Takyon Networks Ltd – 544471): Clarifications submitted; no further immediate action required unless BSE seeks additional information.
  • Companies with pending replies (Adhata Global Ltd – 531286, Anuroop Packaging Ltd – 542865, Milgrey Finance & Investments Ltd – 511018, ZR2 Bioenergy Ltd – 506640): Must respond to BSE’s inquiry promptly. Continued non-response may invite further surveillance or regulatory action.

Important Dates

  • Notice Date: 13 May 2026
  • No specific deadline stated for pending replies; companies are expected to respond at the earliest.

Impact Assessment

Investors/Traders: The attached replies from the three responding companies provide context for the unusual price/volume activity and should be reviewed before trading in those scrips. The four non-responding companies remain under heightened surveillance, and investors should exercise caution.

Market Impact: Medium — abnormal movements in these scrips may indicate speculative activity or material undisclosed information. BSE’s proactive disclosure helps maintain market integrity, but pending replies from four companies leave uncertainty.

Regulatory Risk: Companies that continue to delay responses risk escalated surveillance measures, trading restrictions, or referral to SEBI.

Impact Justification

Routine surveillance circular notifying market participants of BSE's inquiry into abnormal price/volume activity. Three companies have responded; four remain non-compliant pending reply, which may escalate to further action.